v1
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Identifier:nobleid.org/w1/20260526/2AD2AE7E
Type:Journal Article
0 views
Embeddable Badge
[](https://nobleid.org/work/w1/20260526/2AD2AE7E)
Bibliometric Analysis
Impact metrics, research fronts, co-authorship networks →